Literature DB >> 18095988

Expression of HuR in Merkel cell carcinoma and in normal skin.

Virve Koljonen1, Tom Böhling, Caj Haglund, Ari Ristimäki.   

Abstract

BACKGROUND: HuR is a ubiquitously expressed member of the Elav/Hu family of mRNA-binding proteins, and its cytoplasmic expression has been recognised to participate in carcinogenesis. The aims of this study were to explore the expression pattern of HuR in primary Merkel cell carcinoma (MCC), lymph node metastases and non-neoplastic skin.
METHODS: Twenty-two primary MCC samples and five lymph node metastases were evaluated for HuR expression by immunohistochemistry. The data were compared with clinical parameters.
RESULTS: Nuclear and cytoplasmic HuR-staining patterns were observed. Nuclear immunoreactivity was observed in 91% of the primary tumors and in 80% of the lymph node metastases. Cytoplasm was positive in 27% of the primary tumors and in 60% of the lymph node metastases. No cytoplasmic HuR immunoreactivity was detected in non-neoplastic skin. However, moderate to strong nuclear staining was found in normal epidermis and in the epithelium of hair follicles and sebaceous glands. Expression of HuR in MCC did not associate with clinicopathological parameters.
CONCLUSIONS: Primary MCCs and their lymph node metastases as well as non-neoplastic skin show nuclear expression of HuR protein. In contrast to non-neoplastic skin, a subset of MCC tumors show cytoplasmic HuR staining, which may contribute to carcinogenesis in MCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18095988     DOI: 10.1111/j.1600-0560.2007.00762.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Authors:  Federico Bolognani; Anne-Isabelle Gallani; Lena Sokol; David S Baskin; Nicole Meisner-Kober
Journal:  J Neurooncol       Date:  2011-09-21       Impact factor: 4.130

Review 2.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

3.  Cytoplasmic accumulation of the RNA-binding protein HuR stabilizes the ornithine decarboxylase transcript in a murine nonmelanoma skin cancer model.

Authors:  Shannon L Nowotarski; Lisa M Shantz
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

Review 4.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

5.  MicroRNA-125a represses cell growth by targeting HuR in breast cancer.

Authors:  Xu Guo; Yuehan Wu; Rebecca S Hartley
Journal:  RNA Biol       Date:  2009 Nov-Dec       Impact factor: 4.652

Review 6.  Multiple functions of HuR in urinary tumors.

Authors:  Fa Zhang; Zhonglin Cai; Haidi Lv; Wenjuan Li; Mengtian Liang; Xupan Wei; Fenghai Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-28       Impact factor: 4.553

7.  HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis.

Authors:  Michaela Lang; David Berry; Katharina Passecker; Ildiko Mesteri; Sabin Bhuju; Florian Ebner; Vitaly Sedlyarov; Rayko Evstatiev; Kyle Dammann; Alexander Loy; Orest Kuzyk; Pavel Kovarik; Vineeta Khare; Martin Beibel; Guglielmo Roma; Nicole Meisner-Kober; Christoph Gasche
Journal:  Cancer Res       Date:  2017-02-20       Impact factor: 12.701

Review 8.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  HuB/C/D, nPTB, REST4, and miR-124 regulators of neuronal cell identity are also utilized in the lens.

Authors:  Claudine L Bitel; Nora I Perrone-Bizzozero; Peter H Frederikse
Journal:  Mol Vis       Date:  2010-11-04       Impact factor: 2.367

Review 10.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.